A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD
| Status: | Recruiting |
|---|---|
| Conditions: | High Blood Pressure (Hypertension), Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/8/2014 |
| Start Date: | August 2012 |
| Contact: | Maria Pappas |
| Email: | pappas2@iupui.edu |
| Phone: | 3179884591 |
It is estimated that in the United States there are approximately 8 million individuals with
moderate to severe chronic kidney disease (CKD), not on dialysis. Volume expansion plays an
important role in the pathogenesis of hypertension in patients with CKD. For this pilot
study, the investigators hypothesize that administration of chlorthalidone among patients
with moderate to severe CKD will improve BP.
moderate to severe chronic kidney disease (CKD), not on dialysis. Volume expansion plays an
important role in the pathogenesis of hypertension in patients with CKD. For this pilot
study, the investigators hypothesize that administration of chlorthalidone among patients
with moderate to severe CKD will improve BP.
Inclusion Criteria:
- Age greater than 18 years.
- eGFR ≤ 45 ml/min/1.73m2 but ≥20 mL/min/1.73m2.
- Poorly controlled blood pressure by 24-hour ambulatory BP monitoring.
- Treated hypertension: use of at least one antihypertensive drug. One of the drugs
should be either an ACE inhibitor or angiotensin receptor blocker. If these are
contraindicated then use of a beta-blocker is required.
Exclusion Criteria:
- Use of thiazide or thiazide-like drugs in the previous 3 months.
- Use of furosemide in a dose >200 mg/d.
- Ambulatory BP of either ≥160 systolic or ≥100 mmHg by 24-hour ambulatory BP
monitoring.
- Expected to receive renal replacement therapy within the next 3 months.
- Vascular event such as myocardial infarction, heart failure hospitalization, or
stroke within 3 months prior to randomization.
- Pregnant or breastfeeding women or women who are planning to become pregnant or those
not using a reliable form of contraception (oral contraceptives. condoms and
diaphragms will be considered reliable).
- Known hypersensitivity to thiazide or sulfa drugs.
- Organ transplant recipient or therapy with immunosuppressive agents. Nasal or inhaled
corticosteroids will be permitted.
We found this trial at
1
site
Click here to add this to my saved trials
